Loading
Runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins.
James L. Gulley is Co-Director of the Center for Immuno-Oncology in the Center for Cancer Research at the National Cancer Institute. He is a medical oncologist who runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins, having led the PROSTVAC programme and early studies of bintrafusp alfa. His selected paper reports the phase 3 trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. He coordinates immuno-oncology trials across NCI's intramural programme in prostate, bladder and other genitourinary cancers.
| Title | Journal | Year |
|---|---|---|
| Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer | Journal of Clinical Oncology | 2019 |
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares Off-the-shelf cancer vaccines, Immune checkpoint inhibitors.
Shares Off-the-shelf cancer vaccines, National Cancer Institute (NIH), Prostate cancer.
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).